CAR-T Immunotherapy in oncological treatment: literature review
DOI:
https://doi.org/10.33448/rsd-v11i4.27709Keywords:
Neoplasms; Adoptive Immunotherapy; Chimeric Antigen Receptors; Lymphocytes; Immune system.Abstract
Introduction: Immunotherapies are developed to overcome limitations of conventional cancer therapy through stimulating innate immune response against tumor antigen. Objective: Elaborate a review on CAR-T Immunotherapy (Chimeric T Cell Antigen Receptor) in cancer treatment. Methods: Bibliographic survey of systematic reviews published in PubMed in the last 5 years. Results: 21 studies were selected. Antitumor effect occurs through cell lysis, due to CAR-T lymphocytes release of cytokines. Tumor escape is related to tumor's ability to not expose its Major Histocompatibility Complex (MHC) and/or inability of the adaptive immune system to recognize tumor antigens. These molecular targets may be proteins, carbohydrates, or glycolipids, with CD19 standing out as target of this therapy and in neoplasms as leukemia and lymphoma. Four generations of CARs have been described, which differ in terms of co-stimulatory domains and consequent functional efficiency. The therapy is indicated for cases of recurrence/refractoriness of hematological neoplasms, however applicability in solid tumors has been studied. Adverse events of CAR-T immunotherapy described were: cytokine release syndrome, neurotoxicity, anaphylactic shock, autoimmune reactions, B cell aplasia, tumor lysis syndrome and graft-versus-host disease. Conclusions: CAR-T immunotherapy is a promising therapy against relapsed/refractory cancer. It’s mainly used in leukemias and lymphomas. Choice of dose and generation of CARs should be cautious, considering specific molecular targets of each neoplasm and its presence in healthy tissues, avoiding adverse events.
References
Almeida VL., Leitão A., Reina LCB, Montanari CA, Donnici CL; Lopes MTP. Cancer and cell cicle-specific and cell cicle nonspecific anticancer DNA-interactive agents: an introduction. Quím Nova. 2005; 28(1):118-129
Anwer, F., Shaukat, A. A., Zahid, U., Husnain, M., McBride, A., Persky, D., Lim, M., Hasan, N., & Riaz, I. B. (2017). Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy, 9(2), 123–130. https://doi.org/10.2217/imt-2016-0127
Cao, G., Lei, L., & Zhu, X. (2019). Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis. Medicine, 98(42), e17506. https://doi.org/10.1097/MD.0000000000017506
Cao, J. X., Gao, W. J., You, J., Wu, L. H., Liu, J. L., & Wang, Z. X. (2019). The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies. Cytotherapy, 21(7), 769–781. https://doi.org/10.1016/j.jcyt.2019.04.005
Dammeijer, F., Lievense, L. A., Veerman, G. D., Hoogsteden, H. C., Hegmans, J. P., Arends, L. R., & Aerts, J. G. (2016). Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(26), 3204–3212. https://doi.org/10.1200/JCO.2015.66.3955
Drokow, E. K., Ahmed, H., Amponsem-Boateng, C., Akpabla, G. S., Song, J., Shi, M., & Sun, K. (2019). Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis. Therapeutics and clinical risk management, 15, 637–646. https://doi.org/10.2147/TCRM.S203822
Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, et al. Risks and benefits of chimeric antigen receptor T-Cell (CAR-T) therapy in cancer: a systematic review and meta-Analysis. Transfus Med Rev. 2019 Apr;33(2):98-110.
Hao, L., Li, T., Chang, L. J., & Chen, X. (2019). Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety. Current medicinal chemistry, 26(17), 3068–3079. https://doi.org/10.2174/0929867324666170801101842
Holzinger, A., Barden, M., & Abken, H. (2016). The growing world of CAR T cell trials: a systematic review. Cancer immunology, immunotherapy : CII, 65(12), 1433–1450. https://doi.org/10.1007/s00262-016-1895-5
Jin, Z., Xiang, R., Qing, K., Li, X., Zhang, Y., Wang, L., Zhu, H., Mao, Y., Xu, Z., & Li, J. (2018). The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review. Annals of hematology, 97(8), 1327–1335. https://doi.org/10.1007/s00277-018-3368-8
Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA. 1993;90(23):10914-10921.
Li, J., Wu, Z., & Zhao, N. (2019). Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia. Advances in therapy, 36(10), 2881–2894. https://doi.org/10.1007/s12325-019-01056-8
Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol. 2014;32:189-225.
Nagle, K., Tafuto, B., Palladino Kim, L., & Parrott, J. S. (2018). Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis. Medical oncology (Northwood, London, England), 35(11), 144. https://doi.org/10.1007/s12032-018-1204-6
Oppermann CP. Entendendo o câncer. 1 ed. Porto Alegre: Artmed; 2014.
Petrou P. (2019). Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy. Expert review of pharmacoeconomics & outcomes research, 19(5), 529–536. https://doi.org/10.1080/14737167.2019.1651646
Pettitt D, Arshad Z, Smith J, Stanic T, Holländer G, Brindley D. CAR-T cells: a systematic review and mixed methods analysis of the clinical trial landscape. Mol Ther. 2018 Feb 7;26(2):342-353.
Riaz, I. B., Zahid, U., Kamal, M. U., Husnain, M., McBride, A., Hua, A., Hamadani, A. A., George, L., Zeeshan, A., Sipra, Q. R., Raina, A., Rahman, B., Puvvada, S., & Anwer, F. (2017). Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis. Immunotherapy, 9(12), 979–993. https://doi.org/10.2217/imt-2017-0062
Sahlolbei, M., Dehghani, M., Kheiri Yeghane Azar, B., Vafaei, S., Roviello, G., D'Angelo, A., Madjd, Z., & Kiani, J. (2020). Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies. International reviews of immunology, 39(5), 223–232. https://doi.org/10.1080/08830185.2020.1776274
Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 16, 372–385 (2019).
Sohail, A., Mushtaq, A., Iftikhar, A., Warraich, Z., Kurtin, S. E., Tenneti, P., McBride, A., & Anwer, F. (2018). Emerging immune targets for the treatment of multiple myeloma. Immunotherapy, 10(4), 265–282. https://doi.org/10.2217/imt-2017-0136
Werle CH. Avaliação do efeito terapêutico em tumores murinos de cepas atenuadas de Salmonella enterica typhimurium. [Dissertação]. Campinas: Universidade Estadual de Campinas; 2016.
WHO, World Health Organization. (2021). Cancer https://www.who.int/news-room/fact-sheets/detail/cancer
Zeng, Y., Ruan, W., He, J., Zhang, J., Liang, W., Chen, Y., He, Q., & He, J. (2016). Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. PloS one, 11(9), e0162630. https://doi.org/10.1371/journal.pone.0162630
Zhang J, Wang L. The emerging world of TCR-T cell trials against cancer: a systematic review. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819831068.
Zhao, B., Zhang, W., Yu, D., Xu, J., & Wei, Y. (2017). Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget, 8(68), 113105–113119. https://doi.org/10.18632/oncotarget.19373
Zhu, J., Li, R., Tiselius, E., Roudi, R., Teghararian, O., Suo, C., & Song, H. (2017). Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. The Cochrane database of systematic reviews, 12(12), CD011300. https://doi.org/10.1002/14651858.CD011300.pub2
Zhu, Y., Tan, Y., Ou, R., Zhong, Q., Zheng, L., Du, Y., Zhang, Q., & Huang, J. (2016). Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials. European journal of haematology, 96(4), 389–396. https://doi.org/10.1111/ejh.12602
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Gabriela Barge Azzam; Edson Gabriel de Oliveira; Rimon Sobhi Azzam; Francisco Sandro Menezes-Rodrigues
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
